Year |
Citation |
Score |
2014 |
Davidoff AJ, Gardner LD, Zuckerman IH, Hendrick F, Ke X, Edelman MJ. Validation of disability status, a claims-based measure of functional status for cancer treatment and outcomes studies. Medical Care. 52: 500-10. PMID 24638118 DOI: 10.1097/Mlr.0000000000000122 |
0.425 |
|
2014 |
Erten MZ, Davidoff AJ, Zuckerman IH, Shaffer T, Dougherty JS, Ke X, Stuart B. The effect of supplemental medical and prescription drug coverage on health care spending for Medicare beneficiaries with cancer. Value in Health : the Journal of the International Society For Pharmacoeconomics and Outcomes Research. 17: 15-21. PMID 24438713 DOI: 10.1016/J.Jval.2013.11.003 |
0.584 |
|
2013 |
Davidoff AJ, Zuckerman IH, Pandya N, Hendrick F, Ke X, Hurria A, Lichtman SM, Hussain A, Weiner JP, Edelman MJ. A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomes. Journal of Geriatric Oncology. 4: 157-65. PMID 23795223 DOI: 10.1016/J.Jgo.2012.12.005 |
0.403 |
|
2013 |
Davidoff AJ, Weiss SR, Baer MR, Ke X, Hendrick F, Zeidan A, Gore SD. Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines. Leukemia Research. 37: 675-80. PMID 23523473 DOI: 10.1016/J.Leukres.2013.02.021 |
0.325 |
|
2013 |
Davidoff AJ, Erten M, Shaffer T, Shoemaker JS, Zuckerman IH, Pandya N, Tai MH, Ke X, Stuart B. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 119: 1257-65. PMID 23225522 DOI: 10.1002/Cncr.27848 |
0.592 |
|
2013 |
Zandberg DP, Huang TY, Ke X, Baer MR, Gore SD, Smith SW, Davidoff AJ. Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults. Haematologica. 98: 584-90. PMID 23144192 DOI: 10.3324/Haematol.2012.062547 |
0.319 |
|
2012 |
Davidoff AJ, Weiss Smith S, Baer MR, Ke X, Bierenbaum JM, Hendrick F, McNally DL, Gore SD. Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes. Haematologica. 97: 128-32. PMID 22210329 DOI: 10.3324/Haematol.2011.049130 |
0.347 |
|
2012 |
Smith SW, Sato M, Gore SD, Baer MR, Ke X, McNally D, Davidoff A. Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes. Haematologica. 97: 15-20. PMID 22102702 DOI: 10.3324/Haematol.2011.051755 |
0.333 |
|
2012 |
Zuckerman IH, Pandya NB, Stuart BC, Shaffer T, Erten MZ, Ke X, Shoemaker JS, Tai M, Davidoff AJ. Out-of-pocket (OOP) health care expenditure burden for Medicare beneficiaries with cancer. Journal of Clinical Oncology. 30: 6075-6075. DOI: 10.1200/Jco.2012.30.15_Suppl.6075 |
0.57 |
|
2012 |
Ke X, Zuckerman IH, Pandya NB, Shaffer T, Snyder CF, Stuart BC, Davidoff AJ. How do elderly cancer survivors fare? A comparison of characteristics, health status, health behaviors, and spending between Medicare beneficiaries with and without a cancer history. Journal of Clinical Oncology. 30: 6028-6028. DOI: 10.1200/Jco.2012.30.15_Suppl.6028 |
0.52 |
|
2011 |
Hendrick F, Zuckerman IH, Pandya NB, Ke X, Edelman MJ, Davidoff AJ. Validation of a claims-based predicted performance status measure in SEER-Medicare. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6085. PMID 28021771 DOI: 10.1200/Jco.2011.29.15_Suppl.6085 |
0.396 |
|
2011 |
Davidoff AJ, Ke X, Baer MR, Smith SRW, Zandberg D, Hendrick F, Sato M, Greenberg PL, Gore SD. Do Erythropoiesis-Stimulating Agents (ESAs) Affect Survival in Anemic Patients with Myelodysplastic Syndromes (MDS)? Blood. 118: 2794-2794. DOI: 10.1182/Blood.V118.21.2794.2794 |
0.37 |
|
2011 |
Zandberg D, Huang T, Ke X, Baer MR, Gore SD, Smith SW, Davidoff AJ. Chronic Myelomonocytic Leukemia Is Associated with More Frequent and More Rapid Progression to Acute Myeloid Leukemia and Shorter Survival Than Myelodysplastic Syndrome, but Is Less Frequently Treated: Analysis of Surveillance Epidemiology and End Results Data Linked to Medicare Enrollment Claims Blood. 118: 2784-2784. DOI: 10.1182/Blood.V118.21.2784.2784 |
0.35 |
|
2011 |
Ke X, Davidoff A, Zuckerman I, Pandya N, Hendrick F, Smith SW, Baer M, Gore S. 146 Claims-based prediction of performance status (PS) associated with erythropoietic-stimulating agent (ESA) treatment and survival in myelodysplastic syndromes (MDS) patients Leukemia Research. 35: S57. DOI: 10.1016/S0145-2126(11)70148-5 |
0.328 |
|
2010 |
Ke X, Hendrick F, Shaffer T, Davidoff AJ. Out-of-pocket (OOP) spending burden for Medicare beneficiaries with cancer. Journal of Clinical Oncology. 28: 9124-9124. DOI: 10.1200/Jco.2010.28.15_Suppl.9124 |
0.427 |
|
2010 |
Davidoff AJ, Zuckerman IH, Pandya NB, Hendrick F, Ke X, Hurria A, Lichtman SM, Hussain A, Edelman MJ. Development of a performance status prediction model for use in administrative data analyses. Journal of Clinical Oncology. 28: 6006-6006. DOI: 10.1200/Jco.2010.28.15_Suppl.6006 |
0.358 |
|
2010 |
Davidoff AJ, Smith SW, Baer MR, Ke X, Bierenbaum JM, Hendrick F, McNally DL, Gore SD. Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS). Blood. 116: 3815-3815. DOI: 10.1182/Blood.V116.21.3815.3815 |
0.366 |
|
Show low-probability matches. |